(2-phenyl-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone | 1202518-61-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2-phenyl-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone
• 英文别名: ABI-182；(2-Phenyl-1H-imidazol-5-yl)(3,4,5-trimethoxyphenyl)methanone；(2-phenyl-1H-imidazol-5-yl)-(3,4,5-trimethoxyphenyl)methanone
• CAS: 1202518-61-3
• 化学式: C₁₉H₁₈N₂O₄
• 分子量: 338.363
• InChiKey: NTTKPCPMJBTZBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  73.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-苯基咪唑 在 四丁基氟化铵 、 叔丁基锂 、 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 、 正戊烷 为溶剂， 反应 0.67h， 生成 (2-phenyl-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TREATMENT OF CANCER
  [FR] COMPOSÉS DESTINÉS AU TRAITEMENT DU CANCER

  摘要：

  本发明涉及具有抗癌活性的新化合物，制备这些化合物的方法，以及它们用于治疗癌症和耐药肿瘤的用途，例如黑色素瘤、转移性黑色素瘤、耐药黑色素瘤、前列腺癌和耐药前列腺癌。

  公开号：

  WO2011109059A1

文献信息

• [EN] COMPOUNDS FOR TREATMENT OF CANCER<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DU CANCER
  申请人：UNIV TENNESSEE RES FOUNDATION

  公开号：WO2014138279A1

  公开（公告）日：2014-09-12

  The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

  本发明涉及用于治疗癌症的药物组合物，包括BRAF抑制剂（例如维姆拉非尼）和/或MEK抑制剂（例如曲美替尼、RO5068760），与本发明的抗微管化合物或其他已知的微管抑制剂结合使用，以及使用这些组合物来治疗癌症，如黑色素瘤、耐药性癌症和癌症转移。
• COMPOUNDS FOR TREATMENT OF CANCER
  申请人：Miller Duane D.

  公开号：US20090326020A1

  公开（公告）日：2009-12-31

  Compounds according to formula (I) are disclosed where Q is S, N, or O; X is optional, and can be O═, S═, ═N—NH 2 , ═N—OH, or —OH; Y is optional and can be —N(H)—, O, or C 1 to C 20 hydrocarbon; and R 1 and R 2 are each independently substituted or unsubstituted single-, fused- or multiple-ring aryl or (hetero)cyclic ring systems. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.

  根据公式（I）披露的化合物如下：其中Q为S、N或O；X为可选，可以是O═、S═、═N—NH2、═N—OH或—OH；Y为可选，可以是—N(H)—、O或C1至C20碳氢化合物；而R1和R2分别独立地为取代或未取代的单环、融合环或多环芳基或（杂）环烷基环系统。还披露了制备这些化合物的方法、含有这些化合物的药物组合物，以及它们的用途，特别是用于治疗或预防癌症。
• COMPOUND FOR TREATMENT OF CANCER
  申请人：University of Tennessee Research Foundation

  公开号：EP2959900A1

  公开（公告）日：2015-12-30

  A compound, wherein the compound is (2-(1H-indol-3-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone. A pharmaceutical composition comprising the compound is (2-(1H-indol-3-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone and a pharmaceutically acceptable carrier. The compound (2-(1H-indol-3-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone for use in treating prostate cancer, breast cancer, ovarian cancer, skin cancer, lung cancer, colon cancer, leukemia, renal cancer or CNS cancer, or a combination thereof.

  一种化合物，其中化合物为(2-(1H-吲哚-3-基)咪唑-4-基)(3,4,5-三甲氧基苯基)甲酮。 一种药物组合物，包含化合物 (2-(1H-吲哚-3-基)咪唑-4-基)(3,4,5-三甲氧基苯基)甲酮和药学上可接受的载体。 (2-(1H-吲哚-3-基)咪唑-4-基)(3,4,5-三甲氧基苯基)甲酮化合物用于治疗前列腺癌、乳腺癌、卵巢癌、皮肤癌、肺癌、结肠癌、白血病、肾癌或中枢神经系统癌症，或它们的组合。
• Compounds for treatment of cancer
  申请人：University of Tennessee Research Foundation

  公开号：US10301285B2

  公开（公告）日：2019-05-28

  The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.

  本发明涉及一种式 XXII 化合物和一种式 17ya 化合物（在说明书的任何地方都有定义），涉及一种包含这些化合物的组合物，还涉及一种将其用于治疗各种癌症的方法。
• Discovery of Novel 2-Aryl-4-benzoyl-imidazoles Targeting the Colchicines Binding Site in Tubulin As Potential Anticancer Agents
  作者：Jianjun Chen、Zhao Wang、Chien-Ming Li、Yan Lu、Pavan K. Vaddady、Bernd Meibohm、James T. Dalton、Duane D. Miller、Wei Li

  DOI：10.1021/jm100884b

  日期：2010.10.28

  A series of 2-aryl-4-benzoyl-imidazoles (ABI) was synthesized as a result of structural modifications based on the previous set of 2-aryl-imidazole-4-carboxylic amide (AICA) derivatives and 4-substituted methoxylbenzoyl-aryl-thiazoles (SMART). The average IC50 of the most active compound (5da) was 15.7 nM. ABI analogues have substantially improved aqueous solubility (48.9 mu g/mL for 5ga vs 0.909 mu g/mL for SMART-I, 0.137 mu g/mL for paclitaxel, and 1.04 mu g/mL for combretastatin A4). Mechanism of action studies indicate that the anticancer activity of ABI analogues is through inhibition of tubulin polymerization by interacting with the colchicine binding site. Unlike paclitaxel and colchicine, the ABI compounds were equally potent against multidrug resistant cancer cells and the sensitive parental melanoma cancer cells. In vivo results indicated that 5cb was more effective than DTIC in inhibiting melanoma xenograph tumor growth. Our results suggest that the novel ABI compounds may be developed to effectively treat drug-resistant tumors.